Crossmark

Pragmatic pharmacoeconomic analyses by using post-market adverse drug reaction reports: an illustration using infliximab, adalimumab, and the Canada vigilance adverse reaction database

Crossref DOI link: https://doi.org/10.1186/s12913-021-07260-z

Published Online: 2021-11-13

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Maity, Tuhin

Longo, Christopher
License Information

Text and Data Mining valid from 2021-11-13

Version of Record valid from 2021-11-13
More Information

Article History

Received: 30 March 2021

Accepted: 27 October 2021

First Online: 13 November 2021

Declarations

:

: Ethics approval was not required for this work as the research was conducted with anonymous health outcome data available in the public domain. All methods were carried out in accordance with relevant guidelines and regulations.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below